Cyclo (CRLLIF)

Cyclo CRLLIF serves as a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2, disrupting the interaction between HIF1-α and HIF2-α with HIF1-β. It exhibits dissociation constants (KD) of 14.5 μM for HIF1-α and 10.2 μM for HIF2-α within the PAS-B domains.